OptimizeRx Corporation Common Stock (OPRX) is a publicly traded Healthcare sector company. As of May 21, 2026, OPRX trades at $4.92 with a market cap of $95.51M and a P/E ratio of 17.54. OPRX moved +3.00% today. Year to date, OPRX is -62.26%; over the trailing twelve months it is -58.41%. Its 52-week range spans $3.78 to $22.25. Analyst consensus is strong buy with an average price target of $12.00. Rallies surfaces OPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
OptimizeRx Taps DSPs for Programmatic EHR Ads, Targets $19B Pharma Market: OptimizeRx launched a programmatic connection between its EHR network and DSPs, opening access to authenticated, bot-free advertising inventory within clinical workflows and enabling life-sciences marketers to manage reach and frequency independently. The integration positions OptimizeRx to capture share of the $19 billion U.S. pharmaceutical digital display ad market and coincides with momentum in its Dynamic Audience Activation Platform ahead of Q1 2026 results on May 12.
| Metric | Value |
|---|---|
| Price | $4.92 |
| Market Cap | $95.51M |
| P/E Ratio | 17.54 |
| EPS | $0.28 |
| Dividend Yield | 0.00% |
| 52-Week High | $22.25 |
| 52-Week Low | $3.78 |
| Volume | 1.06K |
| Avg Volume | 0 |
| Revenue (TTM) | $109.43M |
| Net Income | $5.13M |
| Gross Margin | 67.25% |
6 analysts cover OPRX: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.00.